Cisplatin-based chemotherapy for postoperative recurrence in non-small cell lung cancer patients: Relation of the in vitro chemosensitive test to clinical response

Higashiyama, Masahiko; Kodama, Kodo; Yokouchi, Hideoki; Takami, Koji; Nakagawa, Hidemitsu; Imamura, Fumio; Minamigawa, Kazuhiko; Kobayashi, Hisayuki

doi:10.3892/or.8.2.279

Cited by 17 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD-DST is now widely used as in vitro chemosensitivity test in Japan, and its usefulness has been clinically demonstrated in the clinical treatment of recurrent NSCLC patients [27]. Kikuchi et al used the same method to investigate the significant associations between expression levels of dozens of genes and chemosensitivity of NSCLCs [28].…”

Section: Discussionmentioning

confidence: 97%

Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer—in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase

et al. 2005

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer—in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase

et al. 2005

View full text Add to dashboard Cite

“…Recent studies evaluating chemosensitivity on several models, including tumor cell lines cultures, tissue cultures, tumor inoculation to an immunodeficient animal, and comparing the results to clinical data have shown that the predictive value of the chemoresistance was always superior to the predictive value of the chemosensitivity [17][18][19][20][21]. A validation of our model with a comparison of the in vitro with the in vivo results, patient per patient, was needed but difficult to obtain.…”

Section: Discussionmentioning

confidence: 96%

A Model of Primary Culture of Colorectal Cancer and Liver Metastasis to Predict Chemosensitivity

Brouquet

Taleb

Lot

et al. 2011

Journal of Surgical Research

View full text Add to dashboard Cite

“…chemosensitivity can be measured directly by the shrinking of tumor size in vitro, and this method of estimating chemosensitivity can yield results in a short time. thus, this assay has been employed in clinical investigations (7)(8)(9)(11)(12)(13)(14). the Japanese Joint committee of the lung cancer registry compiled clinicopathological data for the nsclc Patient Japanese lung cancer registry study for 6,644 nsclc patients who underwent resection.…”

Section: Discussionmentioning

confidence: 99%

“…These findings suggest the need for the appropriate selection of drugs separately for each individual patient. certain in vitro chemosensitivity tests have been established for the identification of an effective anticancer drug for individual cases (1)(2)(3), and the efficacy of these assays has been described in many clinical reports on lung cancer (4)(5)(6)(7)(8)(9) and other malignancies (10)(11)(12)(13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

Chemosensitivity of lung cancer: Differences between the primary lesion and lymph node metastasis

Maniwa

Yoshimura²,

Hashimoto³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. In this study, chemosensitivity tests were performed on both primary lesions (Pls) and lymph node metastases (lMs) from surgically resected non-small cell lung cancer (nsclc). Differences between the results obtained were evaluated. operative specimens were obtained from 13 patients with nsclc [6 with squamous cell carcinoma (sQ) and 7 with adenocarcinoma (AD)] whose lymph nodes were confirmed to be positive for metastasis. Both the Pl and lM from the same patient were examined immediately after resection. the collagen gel droplet-embedded culture drug sensitivity test (cD-Dst) was used as the chemosensitivity test against six anticancer drugs [5-fluorouracil (5-FU), cisplatin, gemcitabine, docetaxel, vinorelbine and sn-38 (an active metabolite of irinotecan)]. When the growth rate, determined by the t/c ratio (t, signal for viable cells in the treated group and c, signal in the control) was less than 50%, the tumor cells were considered to be sensitive to the drug. only in 4 cases (2 sQ and 2 AD) was the chemosensitivity of the primary lesion identical to that of lM. In the sQ cases, chemosensitivity of the primary lesions to 5-FU tended to be consistent with that of LMs. In contrast, the primary lesions in 4 of the 7 AD cases were negative for chemosensitivity to 5-FU; however, LMs were sensitive. In many cases, the chemosensitivity of the Pls to each anticancer drug differed from that of the lMs. In conclusion, both primary and metastatic tumors should be examined to ensure maximum clinical efficacy of in vitro drug-sensitivity testing for adjuvant chemotherapy after complete resection of n1 and n2 nsclc.Introduction the effectiveness of chemotherapy directly affects the prognosis of advanced lung cancer. Adjuvant chemotherapy is expected to contribute to the improvement of the prognosis of patients who undergo curative surgical treatments. the clinical outcome of chemotherapy against non-small cell lung cancer (nsclc) has improved since new drugs have been developed and their combination therapies have been established. However, these drugs are not always equally efficacious in all NSCLC patients. A drug that has curative effects on some patients has sometimes been observed to cause only side effects in other patients. These findings suggest the need for the appropriate selection of drugs separately for each individual patient. certain in vitro chemosensitivity tests have been established for the identification of an effective anticancer drug for individual cases (1-3), and the efficacy of these assays has been described in many clinical reports on lung cancer (4-9) and other malignancies (10-15).Anticancer drugs are expected to be effective not only against primary but also against metastatic lesions. Specifically, adjuvant chemotherapy, after complete resection of lung cancer, targets putative dormant metastasis. However, in certain clinical cases the chemosensitivity of metastatic lesions differs from that of primary lesions. this appears to be normal since the pathological features of the prima...

show abstract

Cisplatin-based chemotherapy for postoperative recurrence in non-small cell lung cancer patients: Relation of the in vitro chemosensitive test to clinical response

Cited by 17 publications

References 0 publications

Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer—in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase

Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer—in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase

A Model of Primary Culture of Colorectal Cancer and Liver Metastasis to Predict Chemosensitivity

Chemosensitivity of lung cancer: Differences between the primary lesion and lymph node metastasis

Contact Info

Product

Resources

About